Gemcitabine with or without Pitavastatin for Advanced Pancreatic Cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study tests whether adding pitavastatin (a cholesterol-lowering drug) to gemcitabine chemotherapy can help treat pancreatic cancer that cannot be surgically removed. You would join if your cancer hasn't grown worse after 2–4 rounds of gemcitabine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Histologically or cytologically confirmed metastatic, recurrent, or locally advanced pancreatic adenocarcinoma (cancer that has spread, come back, or cannot be surgically removed)
- Currently receiving gemcitabine-based chemotherapy for 2–4 cycles with stable or shrinking disease (no radiographic progression)
- Measurable disease on imaging per RECIST 1.1 criteria
- Adequate organ function (blood counts, liver, and kidney function within acceptable ranges)
- ECOG performance status 0–2 (able to carry out light activities)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three medicines to see if they can slow down or shrink pancreatic cancer that has not responded to previous treatments or has come back. It might help if you are generally healthy and your cancer is advanced.
This trial tests a new targeted drug (LM-302) combined with a standard chemotherapy drug (gemcitabine) for people with advanced pancreatic cancer that has progressed after initial treatment. The goal is to see if this combination can slow down or shrink the cancer.
This trial studies a chemotherapy combination (albumin-bound paclitaxel and gemcitabine) as first treatment for pancreatic cancer that cannot be removed by surgery. It aims to improve outcomes by testing how well this treatment works in people with locally advanced or metastatic disease.
This trial tests a combination of three drugs—atebimetinib (a new targeted therapy), gemcitabine, and nab-paclitaxel (two standard chemotherapy drugs)—as a first treatment for pancreatic cancer that has spread beyond the pancreas. The goal is to see if adding atebimetinib helps patients live longer and feel better.
This trial tests whether adding astragalus, an herbal supplement, to the standard chemotherapy drug gemcitabine before surgery can improve outcomes for people with pancreatic cancer. It is a phase 2 study designed to see if the combination is safe and effective.
This study tests a new combination of two drugs for advanced pancreatic cancer. It aims to see if adding an immunotherapy drug (which helps your immune system attack cancer) to standard chemotherapy can help control the cancer better.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.